Tobin C. Schilke
2019 - Revance Therapeutics
In 2019, Tobin C. Schilke earned a total compensation of $1M as Chief Financial Officer at Revance Therapeutics, a 49% decrease compared to previous year.
Compensation breakdown
| Bonus | $25,000 |
|---|---|
| Non-Equity Incentive Plan | $178,123 |
| Option Awards | $299,781 |
| Salary | $407,126 |
| Stock Awards | $86,150 |
| Other | $11,078 |
| Total | $1,007,258 |
Schilke received $407.1K in salary, accounting for 40% of the total pay in 2019.
Schilke also received $25K in bonus, $178.1K in non-equity incentive plan, $299.8K in option awards, $86.2K in stock awards and $11.1K in other compensation.
Rankings
In 2019, Tobin C. Schilke's compensation ranked 9,227th out of 13,971 executives tracked by ExecPay. In other words, Schilke earned more than 34.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,227 out of 13,971 | 34th |
Division Manufacturing | 3,691 out of 5,692 | 35th |
Major group Chemicals And Allied Products | 1,401 out of 2,189 | 36th |
Industry group Drugs | 1,194 out of 1,875 | 36th |
Industry Pharmaceutical Preparations | 886 out of 1,387 | 36th |
Source: SEC filing on March 26, 2020.
Schilke's colleagues
We found five more compensation records of executives who worked with Tobin C. Schilke at Revance Therapeutics in 2019.
2019
Mark Foley
Revance Therapeutics
Chief Executive Officer
2019
L Browne
Revance Therapeutics
Chief Executive Officer
2019
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
2019
Caryn McDowell
Revance Therapeutics
General Counsel
2019
Dustin Sjuts
Revance Therapeutics
Chief Commercial Officer
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019